CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Pharmaceutical Technology
Original article

AstraZeneca pays up to $1.5bn to license Dizal Pharma’s lung cancer drug

PartnershipZegfrovyPositive
AI Analysis

Summary

AstraZeneca licenses Zegfrovy, an already approved lung cancer drug from Dizal Pharma, for up to $1.5 billion with potential for label expansion.

Importance:7/10
Sentiment:
0.60
licensinglung cancerapproved assetlabel expansion
Related Companies

Read the original article

Published by Pharmaceutical Technology on July 14, 2026 2:14 PM

Read Original